Zykadia;Ceritinib; LDK378

  • Purchase Qty: 100
  • Unit: g(s)
  • Fob Unit Price: US $2600
  • Payment Terms:T/T , PayPal
  • Favorite
Shanghai Caerulum Pharma Discovery

Business Type:Manufacturer

Country/Region:China

Ddu Verified

HOT Rank

8/10

Product Information

Description

Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 showed a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib. LDK378 blocks the ALK protein and stops it sending growth signals to cancer cells, which may stop them growing. Ceritinib was approved in April 2014.


Shanghai Caerulum Pharma Discovery is the manufacturer of APIs and intermediates of some of the latest compounds in the market. Our focus is on cancer, diabetes and other therapeutic areas.

 

Shanghai Caerulum Pharma Discovery (CPD) offers high quality and reliable chemical products and integrated biological services including:

1)       Best offer for existing APIs and intermediates

2)       Custom-synthesis APIs and intermediates

3)       DMPK

4)       Biological screening

5)       Drug Safety Evaluation


You Might Also Like
Change a group
Inquiry Cart(0)